BEBAC. Consultancy Services for Bioequivalence and Bioavailability Studies – Ing. Helmut Schütz

bebac.at

What’s new on Bebac.at: Check updates and related news right now. BEBAC offers new content periodically: it has recently posted 10+ news items. It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to BEBAC

  • Over the last three years, pharmaceutical companies have mounted a public relations blitz to tout new cures for the hepatitis C virus and persuade insurers, including government programs such as Medicare and Medicaid, to cover the costs. That isn’t an...

  • by John Otrompke, with Cheryl Scott and S. Anne Montgomery When the United States Food and Drug Administration (FDA) approved the country’s first ever biosimilar on 6 March 2015, it had been a long time coming. After all, the European Union had approved...

  • Use Only as Directed
    via nbcphiladelphia

    During the last decade, more than 1,500 Americans died after accidentally taking too much of a drug renowned for its safety: acetaminophen, one of the nation’s most popular pain relievers. Acetaminophen – the active ingredient in Tylenol...

  • LSPPPO|HEALTHCARE NEWS|October 10, 2013
    via elbiruniblogspotcom.blogspot

    LSPPPO|HEALTHCARE NEWS|October 03, 2013 Healthcare News A Weekly Compilation of Clinical Laboratory and Related Information from The Division of Laboratory Science and Standards October 10, 2013 News Highlights CDC Director: ‘Microbes Didn...

  • The following excerpt is from the company's SEC filing. - Three Phase 3 Epidiolex clinical trials fully recruited above target sample size – on track for initial data in Q1 2016 - - Significant clinical activity in multiple cannabinoid pipeline programs...

You may also like

SOCRATES

SOCRATES Journal is an international, refereed, and indexed scholarly publication focused on public policy, administration, and ph...

MiniWrites – A hub for your creative projects!

A hub for your creative projects!

Bebac.at popular pages

Some worthy website to observe next

Website parameters

  • 56 years

    Domain age

  • 00:01:19

    Visit duration

  • N/A

    Daily visitors

  • N/A

    Bounce rate

Reputation

N/A

Child safety

Good

Trust

Good

Privacy

Audience origins

  • 35.6 %

    India